This study expands the application of an electronic health record (EHR) "nudge" used to prompt physicians' clinical practice to order molecular testing at the time of initial diagnosis for patients with specific types of advanced lung cancer. The primary goal is to have these test results available prior to starting treatment so that physicians can make molecularly-informed treatment decisions. The second goal is to better understand factors that contribute to whether or not the EHR-nudge implementation is successful.
Non Small Cell Lung Cancer Metastatic, Newly Diagnosed NSCLC, Non-Squamous Non-Small Cell Neoplasm of Lung
This study expands the application of an electronic health record (EHR) "nudge" used to prompt physicians' clinical practice to order molecular testing at the time of initial diagnosis for patients with specific types of advanced lung cancer. The primary goal is to have these test results available prior to starting treatment so that physicians can make molecularly-informed treatment decisions. The second goal is to better understand factors that contribute to whether or not the EHR-nudge implementation is successful.
Liquid Biopsy Based NGS in Newly Diagnosed NSCLC
-
Penn Medicine Cherry Hill, Cherry Hill, New Jersey, United States, 08003
Penn Medicine Princeton Health, Plainsboro, New Jersey, United States, 08536
Penn Medicine Washington Township, Sewell, New Jersey, United States, 08080
Penn Medicine Voorhees, Voorhees, New Jersey, United States, 08043
Penn Medicine Lancaster General Health, Lancaster, Pennsylvania, United States, 17602
Penn Presbyterian Medical Center, Philadelphia, Pennsylvania, United States, 19104
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
to
ALL
No
Charu Aggarwal,
Charu Aggarwal, MD, MPH, PRINCIPAL_INVESTIGATOR, Penn Medicine
2025-12